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We ascertained the prevalence of resistant hypertension (RH) among blacks and determined whether RH patients are at greater
risk for obstructive sleep apnea (OSA) than hypertensives. Method. Data emanated from Metabolic Syndrome Outcome Study
(MetSO), a study investigating metabolic syndrome among blacks in the primary-care setting. Sample of 200 patients (mean age
= 63 ± 13 years; female = 61%) with a diagnosis of hypertension provided subjective and clinical data. RH was deﬁned using the
JNC 7and European Society guidelines. We assessed OSA risk using the Apnea Risk Evaluation System ARES), deﬁning high risk
as a total ARES score ≥6. Results. Overall, 26% met criteria for RH and 40% were at high OSA risk. Logistic regression analysis,
adjusting for eﬀects of age, gender, and medical co morbidities, showed that patients with RH were nearly 2.5 times more likely to
be at high OSA risk, relative to those with hypertension (OR = 2.46, 95% CI: 1.03–5.88, P<. 05). Conclusion. Our ﬁndings show
that the prevalence of RH among blacks fell within the range of RH for the general hypertensive population (3–29%). However,
patients with RH were at signiﬁcantly greater risk of OSA compared to patients with hypertension.
1.Introduction
Resistant hypertension (RH) is deﬁned as blood pressure
that remains above goal (<140/90) in spite of concurrent
use of three antihypertensive agents of diﬀerent classes, one
of which being a diuretic; all agents should be prescribed
at optimal dosage amounts. Furthermore, observed blood
pressure (BP) requiring ≥4 medications to reach controlled
BP should be considered resistant to treatment [1, 2].
Longitudinal studies and clinical trials have shown that
RH is a common public health problem. Data from the
ALLHAT trial indicated that the prevalence of resistant
hypertension is 27% [3]. The Outpatient Quality Improve-
ment Network’s Hypertension Initiative, sampling primary-
care clinics in South Carolina, North Carolina, and Georgia
(n = 264,967 hypertensive patients), estimated that the
o v e r a l lp r e v a l e n c eo fR Hi sa b o u t1 6 %[ 4]. Of note, 50%
of the participants in both the National Health and Nutri-
tion Examination Survey (NHANES) [5] and Framingham
Heart Study [6]w e r ea b l et or e a c hat h e r a p e u t i cg o a lo f
<140/90mmHg. Those comprising the group who failed to
reach the therapeutic goal likely included resistant hyperten-
sives and pseudoresistant hypertensives. Given the increased
trends in metabolic syndrome and obstructive sleep apnea2 International Journal of Hypertension
(OSA), RH management will constitute a daunting task,
with important social and economic ramiﬁcations. The
special risk group is more likely to have target-organ damage
and a higher long-term cardiovascular risk than resistant
hypertension patients with controlled hypertension.
Great strides have been made in establishing obstructive
sleep apnea as a target of therapy among hypertensives
[7–9]. This is consistent with results of several multivariate
analyticalmodelsindicatingthatOSArepresentsanindepen-
dent risk factor for hypertension [10–12], and hypertension
constitutes a signiﬁcant predictor of cardiovascular deaths
among patients with OSA [12]. The prevalence of resistant
hypertension itself among men with a diagnosis of OSA may
be as high as 85% (83% (n = 42; AHI ≥ 10/h) [13]a n d
n = 29; AHI ≥ 5/h) [14].
No epidemiologic or clinical study has investigated OSA
riskamongminoritypatientswithRH.Itisevident,however,
that blacks exhibit greater resistance to treatment [15]a n d
black women have the highest prevalence of hypertension
[16] and the lowest blood pressure control [3]. Evidence
also shows that hypertensive blacks with a family history
of hypertension are likely to have higher baseline blood
pressure, and a greater number of oxygen desaturations
and apnea hypoapnea index than their white counterparts
[17]. This study ascertained the prevalence of RH among
black patients in the primary-care setting. It also determined
whether patients with RH are at greater risk for obstructive
sleep apnea (OSA) than hypertensives.
2. Method
2.1. Sample. Data (n = 200, mean age = 63±13 years; female
= 61%) emanated from the Metabolic Syndrome Outcome
Study(MetSO).ThisisanNHLBI-fundedstudyinvestigating
eﬀects of OSA treatment among blacks in the primary-
care setting. Data were obtained from four clinics associated
with SUNY Downstate Medical Center including, Family
Medicine Clinic, Heart Failure Clinic, Diabetes Clinic, and
Leﬀerts Community Health Center.
2.2. Procedures. Study staﬀ approached patients in the
primary-care settings to solicit their participation. Those
agreeing to participate provided informed consent and ﬁlled
out a brief questionnaire on sleep problems, medical history,
and use of medications. They also provided responses to the
Apnea Risk Evaluation System (ARES) Questionnaire [18].
The Apnea Risk Evaluation System (ARES) Questionnaire
was used to identify those at high sleep apnea risk. This
system is recommended in situations where the population
has a large pretest probability. The questionnaire solicits
demographic and anthropometric data, diseases associated
with risk for sleep apnea (i.e., HTN, DM, heart disease,
or stroke), or prior diagnosis of sleep apnea, the Epworth
Sleepiness Scale, and frequency rating for snoring, waking
up choking, and having been told that patients stopped
breathing during sleep. Validation study showed that ARES
hasasensitivityof0.94,speciﬁcityof0.79(basedonaclinical
cut-oﬀ of AHI >5), positive predictive value of 0.91, and
negative predictive value of 0.86 [19].
Clinical data including body mass index (BMI), blood
pressure, high-density lipoprotein cholesterol (HDLC), and
fasting plasma glucose (FPG) or hemoglobin (HbA1c) for
those who have a diagnosis of diabetes were obtained from
the MetSO registry [20–22]. RH was deﬁned using the JNC
7 and European Society guidelines (uncontrolled BP despite
treatment with 3 medications or controlled BP with 4 or
more medications, including a diuretic, in suitable com-
bination and recommended dosage). Uncontrolled HTN is
deﬁned as average systolic and diastolic BP >140/90mm/Hg
(for those without comorbidity), or average clinic SBP
>130mm/Hg or DBP > 80mm/Hg (for those with diabetes
or kidney disease).
2.3. Statistical Analysis. Frequency and measures of central
tendency were used to describe the sample. In preliminary
analyses, Pearson and Spearman correlations were used to
explorerelationshipsbetweenvariablesofinterest.Totestthe
hypothesis that patients with RH were more likely to be at
high OSA risk, compared with those with hypertension, we
utilized multivariate logistic regression modeling. Covariates
entered in the model were age, sex, obesity (deﬁned as
BMI ≥ 30kg/m2), a history of diabetes, dyslipidemia, heart
disease, and depression. Before constructing the model,
correlational analyses were performed to assess associations
betweenhypothesizedpredictorsandthedependentvariable.
All analyses were performed using SPSS (version 18.0; SPSS
Inc. Chicago).
3. Results
Of the sample, 68% were diagnosed with diabetes, 83%
dyslipidemia, and 38% heart disease; 89% were over-
weight/obese. Average systolic and diastolic BP were 135
± 19mmHg and 75 ± 11mmHg, respectively. Blood glu-
cose levels averaged 145 ± 64mg/dL, triglycerides 147 ±
85mg/dL,andLDL97 ±38mg/dL.Overall,26%metcriteria
for RH and 40% were at high OSA risk.
Multivariate logistic regression analysis, adjusting for
eﬀects of age, gender, and medical comorbidities, showed
that patients with RH were nearly 2.5 times more likely to be
at high OSA risk, relative to those with hypertension (OR =
2.46, 95% CI: 1.03–5.88, P <.05). Univariate results for each
of the factors entered in the model are indicated in Table 1.
4. Discussion
Several factors may be liable for low OSA screening rates
in the general population [23–25]. Evidence shows that
healthcare providers do not commonly screen for OSA
among patients with metabolic dysfunctions [26]. This is
compounded by the fact that patients are usually unaware of
the nature and signiﬁcance of sleep apnea and its association
with hypertension [27]. Yet, yearly hypertension contributes
to 14% of deaths occurring in the United States, and to
nearly half of all cardiovascular disease-related deaths [28].
From 1997 to 2007, the death rate caused by high blood
pressure increased to 9.0%, and the actual number of deaths
rose 35.6% [29]. If all hypertensive patients were treatedInternational Journal of Hypertension 3
adequately to reach the goal speciﬁed in current clinical
guidelines, 46,000 deaths might be averted annually [30].
The ﬁrst ﬁnding of our study is that the prevalence
of resistant hypertension among blacks is 26%. This point
estimate falls within the range of RH for the general
hypertensive population (3–29%), albeit towards the high
end.Ourstudyconﬁrmspreviousclinicalstudies,whichhave
tended to include smaller sample sizes (n<50) [13, 14].
No comparisons could be made with other racial/ethnic
g r o u p s ,a sd a t af r o ms u c hg r o u p sw e r en o ta v a i l a b l e .
Notwithstanding this limitation, the study provides useful
data for black hypertensives that may provide a basis for
comparison with other populations in future studies. To our
knowledge, previous studies provided no speciﬁc estimates
for patients of the black race/ethnicity.
The second ﬁnding of our study is that patients with
RH were nearly 2.5 times more likely to be at high OSA
risk, relative to those with hypertension. Of note, this ﬁnding
was independent of patients’ demographic factors and RH-
associated medical conditions. This evidence suggests that
greatereﬀortshouldbemadetoscreenindividualswithresis-
tant hypertension for the presence of OSA. Consistent with
evidence that OSA treatment has signiﬁcant positive eﬀects
in reducing cardiovascular disease risk [31], RH patients
at high risk for OSA should be the target of aggressive
therapeutic management. Evidence suggests that treatment
of OSA among RH patients may facilitate achievement of
optimal BP control.
Findings of this study demonstrate that both sleep apnea
and resistant hypertension represent major public health
concernsamongblackpatients[32].Thisisaseriousconcern
since few blacks (38%) adhered to physician-recommended
OSAassessment[33].OSAisunderdiagnosedbecauseoflack
of awareness among blacks or health professionals [34–38].
There is evidence suggesting that although the frequency of
snoring, the main OSA symptom, is higher among blacks,
they are less likely than whites to report it [39, 40]; 33%
of blacks considered snoring to be normal, relative to 20%
of whites. The observation that blacks with these medical
conditions are often nonadherent to prescribed medical
treatments [41–43] renders clinical management even more
complicated.
The beneﬁts of CPAP treatment have been convincingly
demonstrated among individuals with a dual diagnosis
of hypertension and OSA. Emerging evidence has shown
that long-term adherence to continuous positive airway
pressure (CPAP) therapy suppressd sympathetic activity and
improved blood pressure among patients with RH as well.
Multiple studies have shown signiﬁcant net reduction in
blood pressure among RH patients who received CPAP
treatment [44–46]. In a recent randomized clinical trial
comparing eﬀects of CPAP treatment with conventional
treatment, investigators showed a decrease in 24-hour dias-
tolic BP (−4.9 ± 6.4 versus. 0.1 ± 7.3mmHg, P = .027)
among patients with resistant hypertension. Furthermore,
congruent with current evidence, patients using CPAP for
5.8 hours or longer showed a greater reduction in daytime
diastolic BP, 24-hour diastolic BP, and 24-hour systolic BP
[47]. It is important to conduct randomized CPAP clinical
Table 1: Regression coeﬃcients of the OSA risk factor on resistant
hypertension relative to hypertension, sociodemographic factors,
and medical factors; ∗P<. 05.
Associations of resistant hypertension and sociodemographic
and medical factors with OSA risk
Variables OR 95% C.I.
Resistant hypertension 2.46 1.03–
5.88∗
Age .98 .95–1.01
Sex .65 .30–1.39
Body mass index 2.29 .58–9.05
Dyslipidemia 1.02 .35–2.98
Diabetes 2.29 .95–5.57
Heart disease .99 .99–1.02
Depression .93 .20–4.48
trials among high-risk racial/ethnic minorities, especially
blacks,toassesswhetherCPAPtherapyhassimilarlong-term
eﬀects.
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